Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
Heliostar Presents Q2 2026 Financial and Operating Results with Record Gold Production and Cash Balance